Bristol Myers Squibb (US)

Alle Meldungen

26.11

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference

Download PDF Format (opens in new window) PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2024 Global Healthcare Conference. Christopher Boerner, Ph.D., board chair...

Zur Pressemeldung auf news.bms.com
19.11

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Download PDF Format (opens in new window) Data from more than 20 programs, including new research from cell therapy and targeted protein degradation platforms, showcase the depth and breadth of BMS’ diverse portfolio and ongoing leadership in blood...

Zur Pressemeldung auf news.bms.com
15.11

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Download PDF Format (opens in new window) Opinion based on results from the Phase 3 CheckMate -8HW trial, in which the dual immunotherapy combination of Opdivo and Yervoy demonstrated statistically significant and clinically meaningful improvement...

Zur Pressemeldung auf news.bms.com
15.11

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Download PDF Format (opens in new window) Recommendation based on data from registrational TRIDENT-1 and CARE trials, which demonstrated robust responses and durable activity with repotrectinib in these patient populations If approved,...

Zur Pressemeldung auf news.bms.com
11.11

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

Download PDF Format (opens in new window) Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile...

Zur Pressemeldung auf news.bms.com
05.11

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Download PDF Format (opens in new window) PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024. Samit Hirawat, M.D., Executive...

Zur Pressemeldung auf news.bms.com
31.10

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024

Download PDF Format (opens in new window) Long-term treatment with COBENFY was associated with continued improvements in symptoms of schizophrenia, demonstrating maintenance of effect COBENFY was generally well tolerated over 52 weeks with a side...

Zur Pressemeldung auf news.bms.com
31.10

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

Download PDF Format (opens in new window) Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth Third Quarter Revenues were $11.9 Billion, increasing 8% (+10% Adjusting for Foreign...

Zur Pressemeldung auf news.bms.com
28.10

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024

Download PDF Format (opens in new window) Key presentations include topline safety, efficacy and patient satisfaction data from the 52-week, open label EMERGENT-4 and EMERGENT-5 clinical trials evaluating COBENFY™ (xanomeline and trospium chloride)...

Zur Pressemeldung auf news.bms.com
03.10

Bristol Myers Squibb (US) Bristol Myers Squibb (US)

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Download PDF Format (opens in new window) Approval is based on the CheckMate-77T trial, in which the Opdivo- based regimen demonstrated significantly longer event-free survival compared to the chemotherapy and placebo arm; a high pathologic...

Zur Pressemeldung auf news.bms.com

Wem folgen?

SK Rapid
Folgen
Klima- und Energiefonds
Folgen
KTM
Folgen

Mehr anzeigen

Trends

Tesla
Folgen
Black Friday
Folgen
Transit
Folgen
Menschenrechte
Folgen
Aktionstag
Folgen
Advent
Folgen
Tierschutz
Folgen

Mehr anzeigen

uncovr pure news - Die neue Art Presseinhalte zu recherchieren. Mehr Info